Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study

Abstract Purpose Immunotherapy with atezolizumab and bevacizumab is the current first-line standard of care for unresectable hepatocellular carcinoma (HCC). This study aimed to evaluate the safety and efficacy profile of atezolizumab-bevacizumab in the Indian population, as there are limited studies...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Merin Babu, Ashok Sebastian Komaranchath, Arun Valsan, Arun R. Warrier, Rakesh MP, Wesley M. Jose, Nikhil K. Haridas, Sumi Soman, Manjima P. Nair, Shine Sadasivan, Abhinav Menon, Mohammed Thabrez, Keechilat Pavithran
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2025-07-01
Colecção:BMC Cancer
Assuntos:
atezolizumab
bevacizumab
hepatocellular carcinoma
real world
immune checkpoint inhibitors
Acesso em linha:https://doi.org/10.1186/s12885-025-14400-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados